Human cxcl12 sdf 1α immunoassay

SDF-1α was measured by using an enzyme-linked immunosorbent assay kit (Human CXCL12/SDF-1α immunoassay, R&D Systems, Minneapolis, USA). Urinary albumin and creatinine were measured in single voided urine samples, and the albumin-to-creatinine ratio (ACR) was calculated.

Samples of fasting venous blood were obtained from 18 individuals in the General Hospital of Western Theater Command from May to December 2022. The entire cohort was equally subdivided into subgroups of healthy and T1D individuals with or without C-peptide under 200 pmol/L. The T1D patients who used dipeptidyl peptidase 4 (DPP-4) inhibitor were excluded, because SDF-1α was easily affected by DPP-4 inhibitor [13 (link)]. Blood was centrifuged at 3,000 rpm for 15 minutes at 4°C to remove whole cells, cell debris, and aggregates. The metabolic parameters of blood, including fasting blood glucose (FBG), HbA1c, C-peptide and fasting insulin were tested by the Department of Laboratory Medicine of the General Hospital of Western Theater Command. SDF-1α was measured by using an enzyme-linked immunosorbent assay kit (Human CXCL12/SDF-1α immunoassay, R&D Systems, Minneapolis, USA). Here, 200 pmol/L of plasma C-peptide was chosen as the cut-off for severe insulin deficiency or β cell impairment [14 (link)]. All subjects gave written informed consent before blood collection. The study was conducted according to the principles of the Declaration of Helsinki and approved by the Ethics Committee of the General Hospital of Western Theater Command. The clinical trial was registered at http://www.chictr.org/cn/ under study number ChiCTR2200059448.